BRPI0820351A2 - composição de pelo um ligante agonista receptor de 4-1bb, seu uso, preparado farmacêutico que a compreende, kit de um ou vários recipientes, usos desse kit, uso de um interferon do tipo i´, polinucleotídeo, vetor, célula e usos de um polinucleotídeo - Google Patents

composição de pelo um ligante agonista receptor de 4-1bb, seu uso, preparado farmacêutico que a compreende, kit de um ou vários recipientes, usos desse kit, uso de um interferon do tipo i´, polinucleotídeo, vetor, célula e usos de um polinucleotídeo

Info

Publication number
BRPI0820351A2
BRPI0820351A2 BRPI0820351A BRPI0820351A BRPI0820351A2 BR PI0820351 A2 BRPI0820351 A2 BR PI0820351A2 BR PI0820351 A BRPI0820351 A BR PI0820351A BR PI0820351 A BRPI0820351 A BR PI0820351A BR PI0820351 A2 BRPI0820351 A2 BR PI0820351A2
Authority
BR
Brazil
Prior art keywords
polynucleotide
kit
interferon
vector
cell
Prior art date
Application number
BRPI0820351A
Other languages
English (en)
Portuguese (pt)
Inventor
Agnes Laurence Le Bon
Ignacio Javier Melero Bermejo
Juan Dubrot Armendáriz
Sandra Hervás Stubbs
Original Assignee
Inst Nat Santé Et De La Rech Médicale
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Santé Et De La Rech Médicale, Proyecto Biomedicina Cima Sl filed Critical Inst Nat Santé Et De La Rech Médicale
Publication of BRPI0820351A2 publication Critical patent/BRPI0820351A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0820351A 2007-11-07 2008-11-07 composição de pelo um ligante agonista receptor de 4-1bb, seu uso, preparado farmacêutico que a compreende, kit de um ou vários recipientes, usos desse kit, uso de um interferon do tipo i´, polinucleotídeo, vetor, célula e usos de um polinucleotídeo BRPI0820351A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200702961A ES2336873B1 (es) 2007-11-07 2007-11-07 Composicion farmaceutica para el tratamiento de cancer.
PCT/ES2008/000693 WO2009060112A1 (es) 2007-11-07 2008-11-07 Composición farmacéutica para el tratamiento de cáncer

Publications (1)

Publication Number Publication Date
BRPI0820351A2 true BRPI0820351A2 (pt) 2015-10-27

Family

ID=40351964

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820351A BRPI0820351A2 (pt) 2007-11-07 2008-11-07 composição de pelo um ligante agonista receptor de 4-1bb, seu uso, preparado farmacêutico que a compreende, kit de um ou vários recipientes, usos desse kit, uso de um interferon do tipo i´, polinucleotídeo, vetor, célula e usos de um polinucleotídeo

Country Status (11)

Country Link
US (1) US20110059045A1 (enExample)
EP (1) EP2223701A1 (enExample)
JP (1) JP2011503039A (enExample)
CN (1) CN101951955A (enExample)
AU (1) AU2008324056A1 (enExample)
BR (1) BRPI0820351A2 (enExample)
CA (1) CA2705105A1 (enExample)
ES (1) ES2336873B1 (enExample)
MX (1) MX2010005086A (enExample)
RU (1) RU2010122934A (enExample)
WO (1) WO2009060112A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014005091A2 (pt) 2011-09-05 2017-06-13 Beijing Hanmi Pharmaceutical Co Ltd composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
TWI718086B (zh) * 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
EP3082839A4 (en) * 2013-12-20 2017-08-09 National University of Singapore Differentiation therapy with cd137 ligand agonists
JP6996979B2 (ja) 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019104716A1 (en) * 2017-12-01 2019-06-06 Adagene Inc. Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
WO2006088447A1 (en) * 2005-02-15 2006-08-24 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof
ES2642787T3 (es) * 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso

Also Published As

Publication number Publication date
MX2010005086A (es) 2010-08-10
JP2011503039A (ja) 2011-01-27
AU2008324056A1 (en) 2009-05-14
RU2010122934A (ru) 2011-12-20
US20110059045A1 (en) 2011-03-10
ES2336873B1 (es) 2011-01-24
CN101951955A (zh) 2011-01-19
WO2009060112A1 (es) 2009-05-14
ES2336873A1 (es) 2010-04-16
CA2705105A1 (en) 2009-05-14
EP2223701A1 (en) 2010-09-01

Similar Documents

Publication Publication Date Title
BRPI0815079A2 (pt) Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
CL2007002841A1 (es) Compuestos derivados de indol, antagonistas del receptor de glucagion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes mellitus tipo 2, hiperglucemia, diabetes o resistencia a la insulina.
BRPI0811333A2 (pt) "proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, célula, uso da proteína de fusão e composição farmacêutica"
IL190646A0 (en) Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
DK2156824T3 (da) Sammensætning af solifenacin eller salt deraf til anvendelse i fast formulering
CR11167A (es) Uso de homo y copolimeros para la estabilizacion de formulaciones de principios activos
CL2007003303A1 (es) Molecula de enlace para la proteina lingo-1; polinucleotido que la codifica; vector y celula que lo comprenden; composicion farmaceutica que comprende la molecula de enlace; y su uso para el tratamiento de lesiones del sistema nervioso central.
CL2007003552A1 (es) Compuestos derivados de pirimidina y piridina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno proliferativo celular.
BRPI0815730A2 (pt) Resina absorvente de água adequada para uso em materiais higiênicos
DE602005015476D1 (de) Pulverförmige kosmetische formulierung mit hohem wassergehalt
CL2007002377A1 (es) Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
CL2007002085A1 (es) Anticuerpo o fragmento del mismo especifico para el receptor epha2; polinucleotido que lo codifica; vector y celula huesped que lo comprenden; hibridoma; conjugados del mismo con agentes citotoxicos; composicion farmaceutica que los comprende;su uso
BRPI0908208A2 (pt) Composto derivado de oxazolidinona, medicamento, composição farmacêutica que o contém e uso desse composto.
EA201001223A1 (ru) Стабилизированные белковые композиции
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
CL2008000751A1 (es) Compuestos derivados de cicloprop[d]indolo[2,1-a][2]benzacepina sustituidos con heterociclos; composicion farmaceutica; y uso en el tratamiento de infeccion por hepatitis c.
BRPI0811180A2 (pt) Uso de probióticos ou uma mistura dos mesmos para a preparação de composição farmacêutica utilizável em um ambiente pré e/ou pós-cirúrgico.
BRPI0809977A2 (pt) Uso de um composto, compostos e composição farmacêutica que o contém
BRPI0910656A2 (pt) ´´compostos ligantes de receptor de estrogênio, uso dos mesmos e composição farmacéutica´´
CL2007003640A1 (es) Compuestos derivados de benzamida; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento en que la afeccion es dolor, tales como dolor lumbar y cervical, migrana, dismenorrea, dolor de muelas, entre otros.
BRPI0822033A2 (pt) Composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, kit
CL2007002617A1 (es) Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
BRPI0813341A2 (pt) " uso de compostos, composições curáveis, e, uso de composições curáveis ".
IL193773A0 (en) A peptide which binds to an erythropoietin receptor and pharmaceutical compositions containing the same
DK1610819T3 (da) Stabiliserende formulering til immunoglobulin-G-sammensætninger i flydende eller frysetørret form

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25H Request for change of headquarter rejected

Owner name: PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) , INSTITUT